[1]
|
Krop, I.E., Kim, S.B., Gonzlez-Martin, A., et al. (2014) Trastuzumab Emtanaine versus Treatment of Physician HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Lable, Phase 3 Trial. The Lancet Oncology, 15, 689-699. https://doi.org/10.1016/S1470-2045(14)70178-0
|
[2]
|
Lewis-Phillips, G., Li, G.D., Crocker, L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 68, 9280-9290. https://doi.org/10.1158/0008-5472.CAN-08-1776
|
[3]
|
Krop, I.E., Lin, N.U., Blackwell, K., et al. (2015) Trastuzumab Emtansine (T-DM1) versus Lapatinib plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in Emilia. Annals of Oncology, 26, 113-119. https://doi.org/10.1093/annonc/mdu486
|
[4]
|
Verma, S., Miles, D., Gianni, L., et al. (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791. https://doi.org/10.1056/NEJMoa1209124
|
[5]
|
Perez, E.A., Barrios, C., Eiermann, W., et al. (2017) Trastuzumab Emtansine with or without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study. Journal of Clinical Oncology, 35, 141-148.
https://doi.org/10.1200/JCO.2016.67.4887
|
[6]
|
Montemurro, F., Ellis, P., Anton, A., et al. (2019) Safety of Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Advanced Breast Cancer: Primary Results from the KAMILLA Study Cohort 1. European Journal of Cancer, 109, 92-102. https://doi.org/10.1016/j.ejca.2018.12.022
|
[7]
|
Hurvitz, S.A., Martin, M., Symmans, W.F., et al. (2016) Pathologic Complete Response (pCR) Rates after Neoadjuvant Tras-Tuzumab Emtansine (T-DM1) + Pertuzumab (P) vs Docetaxel + Carboplatin + Trastuzumab + P (TCHP) Treatment in Patients with HER2-Positive (HER2+) Early Breast Cancer (EBC) (KRISTINE). Journal of Clinical Oncology, 34, 500. https://doi.org/10.1200/JCO.2016.34.15_suppl.500
|
[8]
|
Harbeck, N., Gluz, O., Christgen, M., et al. (2016) Final Analysis of WSG-ADAPT HER2+/HR+ Phase II Trial: Efficacy, Safety, and Predictive Markers for 12-Weeks of Neoad-Juvant T-DM1 with or without Endocrine Therapy versus Trastuzumab + Endocrine Therapy in HER2-Positive Hormone Receptorpositive Early Breast Cancer. Cancer Research, 76, Abstract nr S5-03. https://doi.org/10.1158/1538-7445.SABCS15-S5-03
|
[9]
|
von Minckwitz, G., Huang, C.S., Mano, M.S., et al. (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England Journal of Medicine, 380, 617-628.
|
[10]
|
Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015) Proteomics. Tissue-Based Map of the Human Proteome. Science, 347, 1260419.
https://doi.org/10.1126/science.1260419
|
[11]
|
Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) Expression of the HER-2/Neu Proto-Oncogene in Normal Human Adult and Fetal Tissues. Oncogene, 5, 953-962.
|
[12]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
|
[13]
|
Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et al. (2013) Gastric Cancer: ESMOESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, vi57-vi63. https://doi.org/10.1093/annonc/mdt344
|
[14]
|
Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., et al. (2017) Trastuzumab Emtansine versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2/3 Study. The Lancet Oncology, 18, 640-653.
https://doi.org/10.1016/S1470-2045(17)30111-0
|
[15]
|
Shah, M.A., Kang, Y.K., Thuss-Patience, P.C., et al. (2019) Biomarker Analysis of the GATSBY Study of Trastuzumab Emtansine versus a Taxane in Previously Treated HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer. Gastric Cancer, 22, 803-816. https://doi.org/10.1007/s10120-018-00923-7
|
[16]
|
Hotta, K., Fujiwara, Y., Matsuo, K., et al. (2007) Recent Improvement in the Survival of Patients with Advanced Non-Small-Cell Lung Cancer Enrolled into Phase III Trials of First-Line Systemic Chemotherapy. Cancer, 109, 939-948. https://doi.org/10.1002/cncr.22478
|
[17]
|
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M. and Tanimoto, M. (2004) Addition of Platinum Compounds to a New Agent in Patients with Advanced Non-Small-Cell Lung Cancer: A Literature Based Meta-Analysis of Randomised Trials. Annals of Oncology, 15, 1782-1789. https://doi.org/10.1093/annonc/mdh476
|
[18]
|
Lewis Phillips, G.D., Li, G., Dugger, D.L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 8, 9280-9290.
https://doi.org/10.1158/0008-5472.CAN-08-1776
|
[19]
|
Remillard, S., Rebhun, L.I., Howie, G.A. and Kupchan, S.M. (1975) Antimitotic Activity of the Potent Tumor Inhibitor Maytansine. Science, 189, 1002-1005. https://doi.org/10.1126/science.1241159
|
[20]
|
Perera, S.A., Li, D., Shimamura, T., et al. (2009) HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapa-Mycin Combination Therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 474-479. https://doi.org/10.1073/pnas.0808930106
|
[21]
|
Weiler, D., Diebold, J., Strobel, K., Aebi, S. and Gautschi, O. (2015) Rapid Response to Trastu-Zumab Emtansine in a Patient with HER2-Driven Lung Cancer. Journal of Thoracic Oncology, 10, e16-e17.
https://doi.org/10.1097/JTO.0000000000000424
|
[22]
|
Ohashi, K., Hotta, K., Hirata, T., et al. (2017) Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 18, 92-95. https://doi.org/10.1016/j.cllc.2016.06.014
|
[23]
|
Hotta, K., Aoe, K., Kozuki, T., et al. (2018) A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 273-279. https://doi.org/10.1016/j.jtho.2017.10.032
|
[24]
|
Li, B.T., Shen, R., Buonocore, D., et al. (2018) Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial. Journal of Clinical Oncology, 36, 2532-2537.
https://doi.org/10.1200/JCO.2018.77.9777
|
[25]
|
Kobyakov, D.S., Avdalyan, A.M., Klimachev, V.V., Lazarev, A.F., Lushnikova, E.L. and Nepomnyaschikh, L.M. (2015) Non-Small Cell Lung Cancer: HER2 Oncogene Status. Arkhiv Patologii, 77, 3-9. (In Russian)
https://doi.org/10.17116/patol20157723-9
|
[26]
|
Barok, M., Joensuu, H. and Isola, J. (2014) Trastuzumab Emtansine: Mechanisms of Action and Drug Resistance. Breast Cancer Research, 16, Article No. 209. https://doi.org/10.1186/bcr3621
|
[27]
|
Ishimine, Y., Goto, A., Watanabe, Y., et al. (2015) Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Reports in Gastrointestinal Medicine, 2015, Article ID: 132030. https://doi.org/10.1155/2015/132030
|
[28]
|
Janjigian, Y.Y., Riches, J.C., Ku, G.Y., et al. (2015) Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in HER2-Overexpressing Esophagogastric (EG) Tumors Treated with Trastuzumab. Journal of Clinical Oncology, 33, 63 (abstr). https://doi.org/10.1200/jco.2015.33.3_suppl.63
|